

REMARKS/ARGUMENTS

Claims 45-71 are pending in this application.

The Examiner divided the claims into two groups, namely Group I (cited by the Examiner as claims 1-6, 14-22) drawn to a method of treating SARS-coronavirus infection and Group II (cited by the Examiner as claims 33-44) drawn to a kit comprising interferon and instructions. Applicants respectfully elect Group I claims for consideration in this application.

Although the Examiner referred to Group I claims as claims 1-6 and 14-22, Applicants bring to the Examiner's attention the second preliminary amendment filed on November 28, 2006 in this application, in which the claims were re-presented as claims 45-71 to correct mis-numbering of the claims. Thus, Group I claims are currently pending as claims 45-59.

Applicants therefore request search and examination of claims 45-59.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By: 

Richard J. Polley
Registration No. 28,107

Date: 9-6-07

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446